#BEGIN_DRUGCARD DB03264

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
15521

# Chemical_Formula:
C33H58N7O17P3S

# Chemical_IUPAC_Name:
{[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-({[({[(3S)-3-[(2-{[2-(dodecanoylsulfanyl)ethyl]carbamoyl}ethyl)carbamoyl]-3-hydroxy-2,2-dimethylpropoxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}methyl)-4-hydroxyoxolan-3-yl]oxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Dodecyl-Coa

# HET_ID:
DCC

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C33H58N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-24(42)61-17-16-35-23(41)14-15-36-31(45)28(44)33(2,3)19-54-60(51,52)57-59(49,50)53-18-22-27(56-58(46,47)48)26(43)32(55-22)40-21-39-25-29(34)37-20-38-30(25)40/h20-22,26-28,32,43-44H,4-19H2,1-3H3,(H,35,41)(H,36,45)(H,49,50)(H,51,52)(H2,34,37,38)(H2,46,47,48)/t22-,26+,27-,28+,32+/m0/s1

# InChI_Key:
InChIKey=YMCXGHLSVALICC-ZEAOYFJMSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3264

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
949.837

# Molecular_Weight_Mono:
949.282273691

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1U6S

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.35

# Predicted_LogS:
-2.6

# Predicted_Water_Solubility:
2.59e+00 g/l

# Primary_Accession_No:
DB03264

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936623

# PubChem_Substance_ID:
46507209

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01131

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@@H](O)C(C)(C)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H]1O[C@H]([C@H](O)[C@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:05 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Z75208

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
fadR

# Drug_Target_1_Gene_Sequence:
>585 bp
TTGAAGCAAAAACGGCCAAAGTATATGCAGATTATTGATGCAGCAGTAGAAGTCATTGCA
GAAAACGGCTACCACCAGTCACAGGTATCCAAAATTGCCAAACAAGCCGGGGTAGCGGAC
GGCACCATCTATCTCTATTTTAAAAACAAAGAAGATATTTTAATTTCTCTTTTCAAAGAA
AAAATGGGTCAATTTATTGAGCGGATGGAAGAGGACATTAAAGAAAAAGCAACAGCGAAA
GAGAAATTGGCGCTTGTGATTTCAAAGCATTTTTCCCTTTTAGCGGGTGACCATAATCTC
GCCATTGTCACGCAGCTTGAGCTCCGCCAATCCAACTTGGAGCTGCGCCAAAAAATCAAC
GAAATATTAAAAGGCTACTTAAATATTTTGGATGGCATTTTGACGGAAGGTATACAATCA
GGCGAAATAAAAGAAGGCCTCGATGTCCGCCTCGCCCGGCAGATGATTTTTGGAACGATT
GACGAAACTGTGACAACTTGGGTGATGAATGACCAAAAGTACGATCTCGTTGCGCTTTCA
AACAGCGTTTTAGAATTATTGGTATCCGGAATTCACAATAAGTAA

# Drug_Target_1_General_Function:
Involved in DNA binding

# Drug_Target_1_General_References:
9063446	Gothel SF, Schmid R, Wipat A, Carter NM, Emmerson PT, Harwood CR, Marahiel MA: An internal FK506-binding domain is the catalytic core of the prolyl isomerase activity associated with the Bacillus subtilis trigger factor. Eur J Biochem. 1997 Feb 15;244(1):59-65.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5208

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
21979

# Drug_Target_1_Name:
Hypothetical protein ysiA

# Drug_Target_1_Number_of_Residues:
194

# Drug_Target_1_PDB_ID:
1VI0

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00440	TetR_N
PF08359	TetR_C_4

# Drug_Target_1_Protein_Sequence:
>Hypothetical protein ysiA
MKQKRPKYMQIIDAAVEVIAENGYHQSQVSKIAKQAGVADGTIYLYFKNKEDILISLFKE
KMGQFIERMEEDIKEKATAKEKLALVISKHFSLLAGDHNLAIVTQLELRQSNLELRQKIN
EILKGYLNILDGILTEGIQSGEIKEGLDVRLARQMIFGTIDETVTTWVMNDQKYDLVALS
NSVLELLVSGIHNK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P94548

# Drug_Target_1_SwissProt_Name:
FADR_BACSU

# Drug_Target_1_Synonyms:
YsiA protein

# Drug_Target_1_Theoretical_pI:
6.53

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
BX842573

# Drug_Target_2_GenBank_ID_Protein:
38490203

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
fabH

# Drug_Target_2_Gene_Sequence:
>1008 bp
TCAACCCTTCGGCATTCGCACCACCTGGGCGGCATAGCTCAGACCGGCGCCGTAGCCGAT
CAACAGGGCCAGATCGCCGGGCTTGGCCGCGCCGGTCGTCAGTAATTCGGCCATCGCGAG
CGGAATGGAGGCCGCCGAGGTGTTTCCGGTGTGCTCGATATCGTTGGCGACCACCGCGTC
GGGCCGCAACTGCAGGTTCTTGACCAGCAGCTCGTTGATGCGGCTATTGGCCTGATGAGG
GACGAACACGTCTATCTGGTCGGGTCGCACCCCGGCGGCGTCCATCGCGCGCCGACCGAC
GTCGCCCATTTTGAACGCTGCCCAACGGAAGACCGCGGGACCTTCGAGCCGCACAAACGG
GCGTGGGCCGCTGGGATTCTGGGCGAAAGTGATCCAGTCGATGTCCTGCCGTATGGCATC
GGCCTGTTCGCCGTCGCTACCCGCCACGGTTGGTCCAATGCCTTGAAACGGTGTCTCGCC
CACCACCACTGCGGCCGCGCCGTCGGCGAAGATGAAGCAGTTGCCGCGGTCGTACATGTC
TATCGTGGGGGACAGTTTTTCCGTGCCGACCACCAGCATCGTGGCCGCACCTCCGCCCCG
GATCATGTCGGCCGCTGCGCCAAGCGCATATCCGAATCCGGCGCACCCCGCCGAAAGATC
GAACCCGAGTATGCCCTTGGCGCCCAGCGACGCCGCGACCATTGGGGCGGCCGGCGGGGT
TTGCAGGAAATGGGTGTTGGTGGTGACGATCACGCCATCGATGTCGGCCGCCGACAGGCC
GGCGTTCGACAGTGCCCGTCGACAGGCCTCAGTCGCCATGGAAGCCGCCGACTCGTCGTC
GGCGGCGAATCGGCGGGTCTTGATGCCGGTTCGGGTGTAGATCCACTCGTCGGACGAGTC
GATGTGCTGGCATATCTCGTCGTTGGTGACCACGCGTTCGGGCCGGTACGCCCCGACACT
GAGCAGCCCGACGCTCCTGGCGCCGCTGGTCGTGGCGATCTCCGTCAT

# Drug_Target_2_General_Function:
Lipid transport and metabolism

# Drug_Target_2_General_References:
10840036	Choi KH, Kremer L, Besra GS, Rock CO: Identification and substrate specificity of beta -ketoacyl (acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis. J Biol Chem. 2000 Sep 8;275(36):28201-7.
11278743	Scarsdale JN, Kazanina G, He X, Reynolds KA, Wright HT: Crystal structure of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III. J Biol Chem. 2001 Jun 8;276(23):20516-22. Epub 2001 Mar 8.
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3138

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
34873

# Drug_Target_2_Name:
3-oxoacyl-[acyl-carrier-protein] synthase 3

# Drug_Target_2_Number_of_Residues:
335

# Drug_Target_2_PDB_ID:
1HZP

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF08541	ACP_syn_III_C
PF08545	ACP_syn_III

# Drug_Target_2_Protein_Sequence:
>3-oxoacyl-[acyl-carrier-protein] synthase 3
MTEIATTSGARSVGLLSVGAYRPERVVTNDEICQHIDSSDEWIYTRTGIKTRRFAADDES
AASMATEACRRALSNAGLSAADIDGVIVTTNTHFLQTPPAAPMVAASLGAKGILGFDLSA
GCAGFGYALGAAADMIRGGGAATMLVVGTEKLSPTIDMYDRGNCFIFADGAAAVVVGETP
FQGIGPTVAGSDGEQADAIRQDIDWITFAQNPSGPRPFVRLEGPAVFRWAAFKMGDVGRR
AMDAAGVRPDQIDVFVPHQANSRINELLVKNLQLRPDAVVANDIEHTGNTSAASIPLAMA
ELLTTGAAKPGDLALLIGYGAGLSYAAQVVRMPKG

# Drug_Target_2_Reaction:
an acyl-[acyl-carrier-protein] + malonyl-[acyl-carrier-protein] = a 3-oxoacyl-[acyl-carrier-protein] + CO2 + [acyl-carrier-protein]

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role in governing the total rate of fatty acid production. Possesses both acetoacetyl-ACP synthase and acetyl transacylase activities. Has some substrate specificity for long chain acyl-CoA such as myristoyl-CoA. Does not use acyl-CoA as primer. Its substrate specificity determines the biosynthesis of mycolic acid fatty acid chain, which is characteristic of mycobacterial cell wall

# Drug_Target_2_SwissProt_ID:
P0A574

# Drug_Target_2_SwissProt_Name:
FABH_MYCTU

# Drug_Target_2_Synonyms:
3-oxoacyl- [acyl-carrier-protein] synthase III
Beta-ketoacyl-ACP synthase III
EC 2.3.1.41
KAS III
MtFabH

# Drug_Target_2_Theoretical_pI:
4.77

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB03264
